Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Wallach

Showing results (421-430 of 458) with videos related to

Pageof 46
Sort By:
Journal of the American Academy of Dermatology|December 1, 1992
Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled studyL Dubertret, D Wallach, P Souteyrand, et al.
Clinical Trials (London, England)|May 21, 2025
Concordance between clinical trial data use request proposals and corresponding publications: A cross-sectional studyEnrique Vazquez, Joseph S Ross, Cary P Gross, et al.
JAMA Network Open|July 25, 2025
Confounder Selection in Observational Studies in High-Impact Medical and Epidemiological JournalsLuis C L Correia, Rafael F Mascarenhas, Felipe S C De Menezes, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 1, 1981
Unusual phenotypes of human inducer T cells as measured by OKT4 and related monoclonal antibodiesM A Bach, F Phan-Dinh-Tuy, J F Bach, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 26, 1998
Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbetaB S Sylla, S C Hung, D M Davidson, et al.
JAMA Network Open|May 5, 2021
Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved DrugsJennifer E Miller, Michelle M Mello, Joshua D Wallach, et al.
BMJ (Clinical Research Ed.)|May 26, 2018
Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysisJoshua D Wallach, Alexander C Egilman, Sanket S Dhruva, et al.
BMJ Open|March 25, 2019
Submissions from the SPRINT Data Analysis Challenge on clinical risk prediction: a cross-sectional evaluationCynthia A Jackevicius, JaeJin An, Dennis T Ko, et al.
Frontiers in Zoology|February 25, 2014
Experiments in no-impact control of dingoes: comment on Allen et al. 2013Christopher N Johnson, Mathew S Crowther, Chris R Dickman, et al.
Arthritis and Rheumatism|October 1, 1992
Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseasesA P Cope, D Aderka, M Doherty, et al.
Pageof 46

Showing results (421-430 of 458) with videos related to

Sort By:
Pageof 46
Journal of the American Academy of Dermatology|December 1, 1992
Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled studyL Dubertret, D Wallach, P Souteyrand, et al.
Clinical Trials (London, England)|May 21, 2025
Concordance between clinical trial data use request proposals and corresponding publications: A cross-sectional studyEnrique Vazquez, Joseph S Ross, Cary P Gross, et al.
JAMA Network Open|July 25, 2025
Confounder Selection in Observational Studies in High-Impact Medical and Epidemiological JournalsLuis C L Correia, Rafael F Mascarenhas, Felipe S C De Menezes, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 1, 1981
Unusual phenotypes of human inducer T cells as measured by OKT4 and related monoclonal antibodiesM A Bach, F Phan-Dinh-Tuy, J F Bach, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 26, 1998
Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbetaB S Sylla, S C Hung, D M Davidson, et al.
JAMA Network Open|May 5, 2021
Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved DrugsJennifer E Miller, Michelle M Mello, Joshua D Wallach, et al.
BMJ (Clinical Research Ed.)|May 26, 2018
Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysisJoshua D Wallach, Alexander C Egilman, Sanket S Dhruva, et al.
BMJ Open|March 25, 2019
Submissions from the SPRINT Data Analysis Challenge on clinical risk prediction: a cross-sectional evaluationCynthia A Jackevicius, JaeJin An, Dennis T Ko, et al.
Frontiers in Zoology|February 25, 2014
Experiments in no-impact control of dingoes: comment on Allen et al. 2013Christopher N Johnson, Mathew S Crowther, Chris R Dickman, et al.
Arthritis and Rheumatism|October 1, 1992
Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseasesA P Cope, D Aderka, M Doherty, et al.
Pageof 46